Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer

Pharmaceutical Research

Volumn 32, Issue 6, 2015, Pages 2097-2109

  Yang, Xiaoqian ^a,b   Iyer, Arun K ^c,d   Singh, Amit ^c   Milane, Lara ^c   Choy, Edwin ^a   Hornicek, Francis J ^a   Amiji, Mansoor M ^c   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

^c NORTHEASTERN UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

CD44 targeting; HA PEI HA PEG nanoparticle; Multidrug resistance; Ovarian cancer; siRNA delivery

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; MACROGOL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PACLITAXEL; POLYETHYLENEIMINE; SMALL INTERFERING RNA; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CD44 PROTEIN, HUMAN; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; GENE; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MDR1 GENE; MOUSE; NANOENCAPSULATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; RNAI THERAPEUTICS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONIC ACID; MICE, NUDE; NANOPARTICLES; OVARIAN NEOPLASMS; P-GLYCOPROTEINS; PACLITAXEL; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNAI THERAPEUTICS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949116174     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1602-1     Document Type: Article

References (50)

1. Petersen LK, Narasimhan B. Combinatorial design of biomaterials for drug delivery: Opportunities and challenges. Expert Opin Drug deliv. 2008;5(8):837-46.
2. Iyer AK, Singh A, Ganta S, Amiji MM. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 2013;65(13-14):1784-802.
3. Abeylath SC, Ganta S, Iyer AK, Amiji M. Combinatorialdesigned multifunctional polymeric nanosystems for tumortargeted therapeutic delivery. Acc Chem Res. 2011;44(10): 1009-17.
4. Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: An overview. Immunol Cell Biol. 1996;74(2):A1-7.
5. Yadav AK, Mishra P, Jain S, Mishra AK, Agrawal GP. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J Drug Target. 2008;16(6): 464-78.
6. Ganesh S, Iyer AK, Weiler J, Morrissey DV, Amiji MM. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic acids. 2013;2:e110.
7. Ganesh S, Iyer AK, Morrissey DV, Amiji MM. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials. 2013;34(13):3489-502.
8. Ganesh S, Iyer AK, Gattacceca F, Morrissey DV, Amiji MM. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Controll Release Off J Controll Release Soc. 2013;172(3):699-706.
9. Vangara KK, Liu JL, Palakurthi S. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer. Anticancer Res. 2013;33(6):2425-34.
10. Cohen K, Emmanuel R, Kisin-Finfer E, Shabat D, Peer D. Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano. 2014;8(3):2183-95.
11. Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279(11):2047-59.
12. Chen H, Hao J, Wang L, Li Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer. 2009;101(3):432-40.
13. Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez- Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013;19(22):6193-204.
14. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: Current clinical perspectives and future potential. Clin Cancer Res. 2013;19(5):961-8.
15. Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer. 2009;9(6):415-28.
16. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2010;596:47-76.
17. Vergara D, Tinelli A, Iannone A, Maffia M. The impact of proteomics in the understanding of the molecular basis of Paclitaxelresistance in ovarian tumors. Curr Cancer Drug Targets. 2012;12(8):987-97.
18. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-27.
19. GottesmanMM, FojoT, Bates SE.Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.
20. Higgins CF.Multiplemolecular mechanisms for multidrug resistance transporters. Nature. 2007;446(7137):749-57.
21. Duan Z, Choy E, Hornicek FJ. NSC23925, identified in a highthroughput cell-based screen, reverses multidrug resistance. PLoS ONE. 2009;4(10):e7415.
22. Zajchowski DA, Karlan BY, Shawver LK. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther. 2012;11(2):492-502.
23. Donmez Y, Gunduz U. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother Biomed Pharmacother. 2011;65:85-9.
24. Lage H. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets. 2006;7(7):813-21.
25. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrugresistant cancer cells. Cancer Res. 2003;63(7):1515-9.
26. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther. 2004;3(7):833-8.
27. Miele E, Spinelli GP, Di Fabrizio E, Ferretti E, Tomao S, Gulino A. Nanoparticle-based delivery of small interferingRNA: Challenges for cancer therapy. Int J Nanomedicine. 2012;7:3637-57.
28. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967-77.
29. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: Challenges and future directions. Nat Rev Cancer. 2011;11(1):59-67.
30. Resnier P, Montier T, Mathieu V, Benoit JP, Passirani C. A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials. 2013;34(27):6429-43.
31. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 2012;33(29):7138-50.
32. Wang J, Tao X, Zhang Y, Wei D, Ren Y. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. Biomaterials. 2010;31(15):4426-33.
33. Gao Y, Chen Y, Ji X, He X, Yin Q, Zhang Z. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. ACS Nano. 2011;5(12):9788-98.
34. Conde J, de la Fuente JM, Baptista PV. Nanomaterials for reversion of multidrug resistance in cancer: A new hope for an old idea. Front Pharmacol. 2013;4:134.
35. Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin S. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano. 2013;7(2):994-1005.
36. Lamendola DE, Duan Z, Yusuf RZ, Seiden MV. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res. 2003;63(9):2200-5.
37. Duan Z, Zhang J, Choy E, Harmon D, Liu X, Nielsen P. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clin Cancer Res. 2012;18(17):4580-8.
38. Jiang G, Park K, Kim J, Kim KS, Hahn SK. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol Pharm. 2009;6(3):727-37.
39. Jiang G, Park K, Kim J, Kim KS, Oh EJ, Kang H. Hyaluronic acidpolyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers. 2008;89(7):635-42.
40. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000;17(5):521-5.
41. Choi KY, Yoon HY, Kim JH, Bae SM, Park RW, Kang YM. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.ACS Nano. 2011;5(11):8591-9.
42. Shen Y, Wang B, Lu Y, Ouahab A, Li Q, Tu J. A novel tumortargeted delivery system with hydrophobized hyaluronic acidspermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery. Int J Pharm. 2011;414(1-2):233-43.
43. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Controll Release Off J Controll Release Soc. 1999;60(2-3):149-60.
44. Qiao C, Zhang K, Jin H, Miao L, Shi C, Liu X. Using poly(lactic-coglycolic acid) microspheres to encapsulate plasmid of bone morphogenetic protein 2/polyethylenimine nanoparticles to promote bone formation in vitro and in vivo. Int J Nanomedicine. 2013;8:2985-95.
45. Song H, Wang G, He B, Li L, Li C, Lai Y. Cationic lipid-coated PEI/DNA polyplexes with improved efficiency and reduced cytotoxicity for gene delivery into mesenchymal stem cells. Int J Nanomedicine. 2012;7:4637-48.
46. Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev. 2006;58(4):467-86.
47. Choi KY, Min KH, Yoon HY, Kim K, Park JH, Kwon IC. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials. 2011;32(7):1880-9.
48. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006;580(12):2903-9.
49. Materna V, Pleger J, Hoffmann U, Lage H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol. 2004;94(1):152-60.
50. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29(24-25):3477-96.